Alexion Pharmaceuticals Inc.

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Specialty Pharmaceuticals

Other Names/Subsidiaries

  • Achillion Pharmaceuticals
  • Alexion Pharma K.K. (formerly Legend K.K. or Legend Pharma Co.)
  • AstraZeneca PLC
  • AstraZeneca Rare Disease
  • Enobia Pharma
  • LogicBio Therapeutics
  • Orphatec Pharmaceuticals
  • Portola Pharmaceuticals
  • Prolifaron
  • Synageva BioPharma
  • Syntimmune
  • Taligen Therapeutics
  • Wilson Therapeutics
See more in Biomedtracker

Latest on Alexion Pharmaceuticals Inc.

Scrip

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

AstraZeneca intends to bring a self-administered complement C5 inhibitor to market for generalized myasthenia gravis (gMG) now that gefurulimab has delivered positive Phase III results. The product co

Scrip

Asia Deal Watch: JCR And Alexion Build Upon Existing Gene Therapy Alliances

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Anju Ghangurde

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. JCR Adds $825m Gene Therapy Tech D

Generics Bulletin

Amgen And Samsung Soliris Biosimilars Skirt UK Infringement On Claim Construction

 
• By Dean Rudge

Amgen and Samsung Bioepis look set to continue marketing their respective biosimilars to Alexion’s Soliris (eculizumab) in the UK, after the UK High Court of Justice’s Patents Court ruled that the fir

Pink Sheet

Confirmatory Trials: Industry Wants Timely Protocol Feedback, More Clarity On ‘Due Diligence’

 
• By Sue Sutter

Industry comments on two recent US Food and Drug Administration guidance documents on accelerated approval seek clear timelines for agency feedback on confirmatory study protocols and a better underst